{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:37:56Z","timestamp":1786736276420,"version":"build-2736575974"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Cancer"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/ijc.ijc_303_18","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T09:10:17Z","timestamp":1567069817000},"page":"211","source":"Crossref","is-referenced-by-count":5,"title":["A prospective, randomized study to compare the combination of imatinib and cytarabine versus imatinib alone in newly diagnosed patients with chronic phase chronic myeloid leukemia"],"prefix":"10.4103","volume":"56","author":[{"given":"Priyanka","family":"Samal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prantar","family":"Chakrabarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"UttamK","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0019-509X.263029-1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4103\/0971-5851.89792","article-title":"Changing trends of chronic myeloid leukemia in greater Mumbai, India over a period of 30 years","author":"Dikshit","year":"2011","journal-title":"Indian J Med Paediatr Oncol","ISSN":"https:\/\/id.crossref.org\/issn\/0971-5851","issn-type":"print"},{"key":"key-10.4103\/0019-509X.263029-2","unstructured":"American Cancer Society. How Is Chronic Myeloid Leukemia Staged? Available from: https:\/\/www.cancer.org\/cancer\/chronic-myeloid-leukemia\/detection-diagnosis-staging\/staging.html. [Last accessed on 2018 Mar 13]."},{"key":"key-10.4103\/0019-509X.263029-3","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","article-title":"The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells","author":"Deininger","year":"1997","journal-title":"Blood"},{"key":"key-10.4103\/0019-509X.263029-4","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: A European LeukemiaNet Study","author":"Baccarani","year":"2009","journal-title":"Blood"},{"key":"key-10.4103\/0019-509X.263029-5","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.263029-6","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"key-10.4103\/0019-509X.263029-7","unstructured":"Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003 (http:\/\/ctep.cancer.gov), Published Date: August 9, 2006."},{"key":"key-10.4103\/0019-509X.263029-8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"key-10.4103\/0019-509X.263029-9","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/0019-509X.263029-10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"key-10.4103\/0019-509X.263029-11","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"key-10.4103\/0019-509X.263029-12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/1097-0142(19870101)59:1<197::AID-CNCR2820590137>3.0.CO;2-8","article-title":"Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia","author":"Sokal","year":"1987","journal-title":"Cancer"},{"key":"key-10.4103\/0019-509X.263029-13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"key-10.4103\/0019-509X.263029-14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3816\/CLK.2008.n.016","article-title":"Imatinib compared with imatinib\/cytarabine for the first-line treatment of early philadelphia chromosome\u2013positive chronic myeloid leukemia: Results of a randomized clinical trial of the Mexican Collaborative Leukemia Group","author":"Hurtado-Monroy","year":"2008","journal-title":"Clin Leuk"},{"key":"key-10.4103\/0019-509X.263029-15","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2003-04-1010","article-title":"Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase","author":"Gardembas","year":"2003","journal-title":"Blood"},{"key":"key-10.4103\/0019-509X.263029-16","doi-asserted-by":"crossref","unstructured":"Giles FJ. New directions in the treatment of imatinib failure and\/or resistance. Semin Hematol 2009;2(Suppl. 3):S27-33.","DOI":"10.1053\/j.seminhematol.2009.01.011"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:39:50Z","timestamp":1786732790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_303_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"alternative-id":["263029"],"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_303_18","relation":{},"ISSN":["0019-509X"],"issn-type":[{"value":"0019-509X","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}